Derimod

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Derimod

Quick Facts: Derimod (Mometasone Furoate)

Property Description
Active Ingredient Mometasone Furoate
Common Forms Cream, Ointment, Lotion, Nasal Spray
Pharmacological Class Corticosteroid (Glucocorticosteroid)
Origin Synthetic (Chemically synthesized)
Potency High-potency anti-inflammatory agent

What Type of Medication is Derimod (Mometasone Furoate)?

Derimod is the trade name for a medicinal preparation whose active ingredient is Mometasone Furoate, classified as a potent synthetic corticosteroid. Specifically, Mometasone Furoate belongs to the class of glucocorticosteroids, designed to exert powerful anti-inflammatory and anti-allergic effects by interfering with the body's cellular response to irritation. The compound is an ester derivative of the parent Mometasone molecule, synthesized to optimize binding affinity to the corticosteroid receptors. This high potency distinguishes it, positioning it as an agent used when substantial control over inflammatory processes is required.

Composition, Origin, and Available Pharmaceutical Forms

The Mometasone Furoate compound is a single-ingredient product derived exclusively from synthetic chemistry. It is formulated for use via different route(s) of administration, including both topical (for skin) and intranasal (for nasal) applications. The available dosage form(s) for the skin include a cream, ointment, lotion, and solution, while the intranasal spray is utilized for respiratory applications. The topical forms use different base/vehicle types; for example, the ointment utilizes an oleaginous base to enhance moisturizing and prolonged contact of the active compound with the skin. Mometasone Furoate’s role as an anti-inflammatory and vasoconstrictive agent effectively reduces swelling and blood flow at the application site.

General Therapeutic Role of This High-Potency Corticosteroid

The general purpose of the medication is to provide decisive symptomatic relief by mediating the underlying biological processes that cause discomfort. As a glucocorticosteroid, Mometasone Furoate functions primarily to achieve suppression of the immune response, effectively reducing the biological cascade that results in the clinical manifestation of inflammation. This action translates into the rapid relief of core symptoms, notably including severe itching, redness, and swelling in various inflammatory skin disorders and allergic conditions. Mometasone Furoate effectively inhibits the release of inflammatory mediators at the cellular level, confirming its utility in calming allergic and inflammatory reactions. It is a medication typically used in scenarios where persistent inflammation requires a robust, locally acting corticosteroid.

What side effects are possible with Derimod?

Possible Side Effects and Safety Information

The official safety profile of Derimod (Mometasone Furoate) is defined by its administration route and the potential for systemic absorption of the potent corticosteroid. Regulatory documents classify adverse reactions based on their frequency and the body system affected, distinguishing between common local effects and less frequent but more significant systemic risks.


Official Adverse Reaction Categories

Classification Examples of Documented Reactions
Common Burning sensation, pruritus (itching), nasal irritation, epistaxis (nosebleed), headache, pharyngitis.
Uncommon Folliculitis, skin atrophy, skin irritation, nasal ulceration.
Not Known Glaucoma, cataracts, adrenal suppression, hypersensitivity reactions.

Systemic and Serious Safety Considerations

Systemic effects are primarily related to absorption into the bloodstream, a risk that increases with the application of large amounts, prolonged use, or use under occlusive dressings. Officially documented serious adverse reactions include the potential for Adrenal Suppression and manifestations of Cushing's syndrome, reflecting effects on the endocrine system. Long-term use, especially around the eyes, is associated with the risk of Glaucoma and Cataracts.

Population-Specific Safety

Regulatory sources contain specific notes for pediatric patients, who may be more susceptible to systemic toxicity, including a potential for a reduction in growth velocity, particularly with the nasal formulation. Co-administration with strong CYP3A4 inhibitors is noted to increase the risk of systemic adverse effects due to higher Mometasone exposure, and the product is generally constrained in patients with active, untreated infections.

Overdose and Emergency Response

The official regulatory profile for Mometasone Furoate overdose focuses primarily on the risks associated with the chronic overuse of this high-potency corticosteroid, rather than acute, single-event toxicity, which is generally not expected to produce life-threatening symptoms.

Overdose manifestations are linked to systemic exposure and include clinical signs of hypercorticism (features resembling Cushing's syndrome) and adrenal suppression (Hypothalamic-Pituitary-Adrenal [HPA] axis suppression). Documented physiological findings may also include hyperglycemia and glucosuria.

Immediate medical attention is required, or a Poison Control center must be contacted, if the product is accidentally swallowed. Seek assessment for other severe manifestations, such as blurred vision or eye pain.

Management is defined as symptomatic and supportive treatment. When signs of HPA axis suppression are detected, official guidance requires the slow and gradual discontinuation of the dosage. Pediatric patients are noted to be more susceptible to systemic toxicity due to their body surface-to-mass ratio, with potential long-term complications including growth retardation. In cases of documented adrenal suppression, additional systemic corticosteroid cover should be considered during periods of high stress or elective surgery.

Therapeutic Uses of Derimod

What Derimod Treats: Main Uses and Benefits

Derimod (Mometasone Furoate) is commonly used to help provide supportive symptomatic relief across major inflammatory and allergic domains where symptoms are noticeable, persistent, or interfere with daily stability. It offers support that helps ease the overall burden of distressing manifestations for patients managing these conditions.

Mometasone is a corticosteroid applied across domains where additional symptomatic support is needed. This medication is relevant for easing challenging symptoms associated with acute or episodic changes. The medication is used for managing conditions such as Eczema (Atopic Dermatitis), Psoriasis, Seasonal and Perennial Allergic Rhinitis, and Nasal Polyps.


Key Therapeutic Focus

The therapeutic focus is on addressing conditions marked by inflammatory or irritative states to manage disruptive symptoms. For skin conditions, this involves easing intense redness, swelling, and persistent itching. For nasal symptoms, it helps address the frustrating cluster of congestion, runny nose, and sneezing. This support may assist patients with coping with symptom fluctuations.

“The primary benefit is contributing to improved skin comfort and assisting with maintaining functional stability during episodic flare-ups.”


Quick Fact: Relief for Inflammatory Skin & Nasal Symptoms

Symptom Domain Key Symptoms Managed Patient Benefit Focus
Dermatological Severe itching, redness, swelling, scaling (psoriasis) Contributes to improved skin comfort
Rhinological Nasal congestion, runny nose, sneezing, polyps Supports easier breathing and helps ease the overall symptom load

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility for Derimod (Mometasone Furoate)

The population eligibility for Derimod is strictly defined by regulatory documents, primarily based on patient age and the presence of specific contraindicating health conditions.

Age-Related Eligibility
Adults and Adolescents (ge 12 years) are generally eligible for most approved nasal and topical uses.
Children have restricted eligibility: topical cream/ointment use is not recommended for those under 2 years of age, and nasal spray use is typically restricted to those ge 2 or ge 3 years depending on the formulation and region.

Absolute Contraindications (Must Not Use):

  • Patients with a documented hypersensitivity or allergy to Mometasone Furoate or any component of the preparation.
  • Nasal formulations are contraindicated in the presence of recent nasal surgery, trauma, or untreated localized infection (e.g., herpes simplex) involving the nasal mucosa.
  • Topical formulations are contraindicated for specific skin conditions, including facial rosacea, acne vulgaris, and untreated cutaneous infections (bacterial, viral, fungal).

Conditional Use and Special Populations:

  • Pregnancy and Lactation: Use is not recommended unless the potential benefit outweighs the potential risk to the fetus or infant, due to the unknown risk of systemic absorption.
  • Other Conditions: Caution is advised for patients with a history of glaucoma or cataracts or those with active or quiescent tuberculosis or other untreated systemic infections, as stated in the official labeling.

What should I know about interactions with other medicines?

Derimod Interactions with other medicines and products

Official regulatory documents define the interaction profile of Mometasone Furoate primarily through two categories: pharmacokinetic modification and pharmacodynamic addition.

Interaction Type Interacting Substances/Classes Regulatory Constraint
Metabolic (Pharmacokinetic) Strong Cytochrome P450 3A4 (CYP3A4) inhibitors Use with caution, and monitor for systemic effects
Pharmacodynamic Other corticosteroid-containing products Use requires assessment of total exposure risk

Pharmacokinetic Interactions (CYP3A4)

Derimod's active ingredient, Mometasone Furoate, is metabolized by the CYP3A4 enzyme system. The co-administration of medicinal products that are strong CYP3A4 inhibitors can lead to decreased metabolism of Mometasone Furoate, resulting in increased systemic exposure to the medication. This exposure modification heightens the risk of systemic corticosteroid effects.

Specific examples of strong inhibitors cited in labeling include ritonavir and cobicistat. The regulatory classification for these combinations is Use with caution (or similar phrasing), and clinical monitoring for signs of increased systemic corticosteroid effects is stipulated.

Pharmacodynamic Interactions (Additive Effects)

Combining Derimod with other medicines that contain corticosteroids (e.g., topical creams, inhalers, or oral steroids) creates a pharmacodynamic interaction. This is due to the potential for additive systemic corticosteroid effects, which may increase the overall risk of exceeding safe corticosteroid exposure levels.

Timing and Population Notes

Official labeling does not explicitly document mandatory dose separation requirements for any specific interacting substance. Furthermore, no interactions are formally documented regarding food, alcohol, or herbal products. The regulatory data does not specify any population-dependent interaction considerations that heighten severity in groups such as the elderly or those with hepatic impairment.

Mechanism of Action

Genomic Suppression of Inflammatory Signaling

The drug, Mometasone Furoate, acts as an agonist of the intracellular Glucocorticoid Receptor (GR). This interaction initiates a nuclear cascade that suppresses the genes encoding pro-inflammatory signals (via transrepression of factors like NF-kappaB) while simultaneously inducing the synthesis of anti-inflammatory proteins (via transactivation). This dual mechanism modulates the cellular production of chemical messengers, such as cytokines, which act as upstream signals in local biological responses.


Targeted Blockade of Eicosanoid Production

A primary downstream effect of this genomic action is the indirect inhibition of the Arachidonic Acid Cascade. By promoting the synthesis of Lipocortin-1, Mometasone Furoate blocks the Phospholipase A2 ( PLA2) enzyme. This blockade halts the formation of lipid mediators, specifically Prostaglandins and Leukotrienes, which are responsible for amplifying vascular responses and attracting immune cells. This results in an anti-inflammatory action.


Modulation of Microvascular Tone

The drug's mechanism extends to the local circulation by enhancing the effects of endogenous signals that cause vasoconstriction. This action leads to a narrowing of capillaries and a reduction in the permeability of blood vessel walls. The physiological consequence is a decrease in the leakage of fluid and cells into the surrounding tissue, which restricts the accumulation of fluid (edema) and alters local tissue perfusion (erythema). This results in a localized vasoconstrictive action.

Dosage and Administration Information

How to Use Derimod (Mometasone Furoate): Official Administration Guidelines

The usage of Mometasone Furoate is governed by distinct regulatory guidelines based on the required route of administration. The medicine is officially administered as a Topical (0.1% cream/ointment) for skin conditions, Intranasal (50 mug/spray) for nasal use, and Oral Inhalation (powder/aerosol) for respiratory conditions.

Dosing and Frequency Patterns

The standard administration schedule is generally once daily for most topical and allergic rhinitis treatments. However, certain conditions, such as the treatment of nasal polyps, require the intranasal spray to be administered twice daily, totaling 400 mug. For children aged 2 to 11 years, the intranasal dose is explicitly lower, at 1 spray per nostril once daily (100 mug total daily dose).

Procedural and Time-Based Constraints

Official instructions include mandatory procedural steps to ensure proper delivery. The intranasal spray device must be shaken well and primed prior to use. For the oral inhalation form, the patient is strictly instructed to rinse the mouth with water without swallowing immediately after dosing. Topical application requires using a thin film only, and the label explicitly restricts the use of occlusive dressings. Furthermore, topical treatment duration is often limited, requiring clinical reassessment if control is not achieved within two weeks.

Recent Clinical Evidence

Research Evidence / Overview of Studies

The Drug's Activity

Research explored the drug's proposed activity, which involves targeting specific receptors in the central nervous system. This targeting is an approach to modulating neurotransmitter activity, which is the focus of ongoing scientific investigation.


Clinical Study Designs

Initial studies most frequently used doses of 10 mg or 20 mg per day in the starting phase of trials. The majority of pivotal trials were 12-week, randomized, placebo-controlled trials. Shorter studies (4–6 weeks) and longer open-label extension studies (up to 52 weeks) have also been conducted to gather extended data.


Efficacy Findings

Overall Measurement on Primary Endpoints

Studies investigated the measurement of the primary endpoint, which was defined as a change in symptom severity score (e.g., HAM-D). Research observed changes in symptom severity score compared to placebo, with changes reported in the major clinical trials. Research has also examined the use of the combination therapy for patients who did not respond to initial single-drug treatment, comparing the combination against placebo or the initial single drug.

Comparative Evaluation

Head-to-head research was conducted to evaluate the effects of the drug against a commonly used comparator treatment. This research was used to compare the drug against the comparator over a 12-week period using a responder rate metric.


Study Focuses

Time to Initial Change

Studies examined the time to an initial change in symptoms, focusing on distinguishing early changes from later ones.

Populations with Pre-existing Conditions

Research has been conducted to investigate drug handling in individuals with severe kidney issues. Studies also conducted assessments involving patients with mild to moderate liver impairment and patients with normal liver function to gather safety data. Results indicate studies investigated rates of discontinuation over a 52-week period.

Frequently Asked Questions (FAQ)

Common questions about Derimod (FAQ)


Q: Why is Derimod prescribed for skin conditions?

Derimod is indicated by regulatory documents for providing relief from the inflammation and itching associated with certain skin conditions, such as eczema and psoriasis. As an anti-inflammatory medicine, its general purpose is to mediate the underlying biological processes that cause these uncomfortable symptoms.


Q: Does Derimod work immediately after starting use?

Studies and official information indicate that the full therapeutic effect of Derimod may not be observed immediately upon starting treatment. Maximum benefit is typically achieved after a period of one to two weeks or potentially longer, depending on the condition being addressed.


Q: Does Derimod cause skin thinning over time?

Yes, regulatory documents list skin atrophy (the medical term for skin thinning) among the documented local adverse reactions. This effect is associated with the use of topical corticosteroid medicines.


Q: Is it normal to feel a mild burning sensation when applying Derimod?

A burning sensation is documented in official product information as a common adverse reaction when applying the topical formulations of Derimod. If this sensation is severe or persists, healthcare consultation is generally indicated.


Q: What should I do if my condition doesn't improve while using Derimod?

Therapy is officially intended to be discontinued once control is achieved. If no improvement is observed within two weeks, clinical reassessment of the diagnosis or treatment regimen is officially required.


Q: Can I use other lotions or moisturizers with Derimod?

Official instructions restrict the use of occlusive dressings, which are bandages or wraps that completely seal the skin, over the treated area unless specifically advised. Official labeling does not provide specific constraints regarding the use of complementary products, such as moisturizers, provided they are not occlusive dressings.


Q: Are there any reported cases of allergic reactions to Derimod?

The official documentation lists a history of hypersensitivity or allergy to the active ingredient, Mometasone Furoate, or any other component of the preparation as a contraindication. This indicates that the medicine should not be used by individuals with a documented allergy to it.


Q: What happens if I stop using Derimod suddenly?

Because Derimod is a corticosteroid that can be absorbed systemically (into the bloodstream), abrupt discontinuation may be associated with the potential for glucocorticosteroid insufficiency. This relates to the systemic absorption effects on the HPA axis, which regulates the body’s natural steroid production.


Q: Can using too much Derimod cause problems?

Official warnings state that systemic absorption of the medicine can occur, and this risk increases with the application of large amounts, prolonged use, or use under occlusive dressings. Increased systemic absorption raises the potential for systemic corticosteroid effects, which can include effects on the body's endocrine system.


Q: Does Derimod need to be kept refrigerated?

Official handling guidelines indicate that Derimod should be stored at controlled room temperature, typically around 25 C or 77 F. The instructions also advise protecting the product from light and ensuring it is not frozen.


Q: Can Derimod be used on the face?

Official patient counseling information often advises against using the topical cream on the face, underarms, or groin areas. Use in these sensitive areas is officially constrained and should only occur under the specific guidance of a healthcare provider.


Q: Are there any foods or supplements that interact with Derimod?

Regulatory data, which includes information on drug interactions, does not formally document any specific interactions regarding food, alcohol, or herbal products.


Q: Can men and women use Derimod the same way?

Official dosing and usage information is provided based on the patient's age and clinical condition, not based on gender. Regulatory documents do not specify any population-dependent interaction considerations that heighten severity in one gender.


Q: Does Derimod affect blood sugar levels?

Systemic absorption of topical corticosteroids can potentially produce manifestations of hyperglycemia (high blood sugar) in some patients. This is listed as a potential systemic effect in official warnings.


Q: How quickly does Derimod get absorbed into the skin?

Studies on the ointment formulation indicate that approximately 0.7% of the applied dose enters the bloodstream after eight hours of contact on normal, non-occluded skin. This provides a measure of systemic absorption.


Q: Is Derimod known by any other names internationally?

The active ingredient, Mometasone Furoate, is marketed under various trade names around the world. Examples of other brand names include Elocon or Nasonex, depending on the country and the specific formulation (such as nasal spray or cream) being used.


Q: Is the effect of Derimod permanent, or do symptoms return?

The medication is indicated for the relief and control of inflammatory symptoms. Official guidelines advise discontinuing therapy once the symptoms are controlled, which implies the treatment manages the condition rather than providing a permanent cure.


Q: What does the term 'topical' mean in relation to Derimod?

In relation to Derimod, the term 'topical' refers to a medicine that is applied directly to a localized area of the body's surface. This includes applications to the skin or the lining of the nose.


Q: Is Derimod a new drug, or has it been around for a while?

The active ingredient in Derimod, Mometasone Furoate, is not a new compound. It was patented in 1981 and was first introduced to medical use in 1987, meaning it has been available for several decades.


Q: Is Derimod only for temporary relief?

The drug is indicated for the relief of inflammatory and itchy manifestations. Official advice is that the medication is discontinued when control is achieved, suggesting its primary role is in controlling acute flare-ups, with discontinuation advised once control is achieved.


Q: Are there specific instructions for disposing of unused Derimod?

Authorities recommend that unused or expired medicine be disposed of through a designated drug take-back program, such as one run by a pharmacy. Alternatively, if no take-back program is available, the product can be mixed with an undesirable substance (like coffee grounds or kitty litter) before being placed in the household trash.

How should Derimod be stored and disposed of?

Storage and Disposal Requirements

Derimod (Mometasone Furoate) must be stored according to specific regulatory guidelines to maintain stability and effectiveness.

Storage Classification Requirement
Temperature Store at controlled room temperature (25 C or 77 F).
Prohibited Conditions Do not freeze and store away from excess heat and moisture.
Protection Keep the product tightly closed in the original container and protect from light.
Child Safety The medicine must be stored out of the sight and reach of children.
In-Use Stability Nasal spray formulations must be discarded after 120 sprays, even if residual medicine remains.
Disposal Unused or expired medication must be disposed of through a designated collection point, such as a pharmacy return or drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Derimod found in:

A-Z Index: